Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of UMC119-01 in Infants at High Risk for BPD
NCT03631420Phase 1Recruiting
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Dec 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UMC119-01 in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Adverse Events at 3 months. Started Oct 2018; status: recruiting.
02
Drugs
UMC119-01
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03631420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631420.